Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Critical Mineral Executive Order Issued by President Donald Trump (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Esperion Therapeutics Inc ESPR

Healthcare Biotechnology
Esperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (CVD) and are struggling with elevated low-density lipoprotein cholesterol (LDL-C). Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. Its NEXLETOL and NEXLIZET (bempedoic acid... see more

Current News (NDAQ:ESPR)

Esperion to Participate in 24th Annual Needham Virtual Healthcare Conference

GlobeNewswire 1 day ago

Esperion Aligns with U.S. Food and Drug Administration to Initiate Phase 3 Clinical Trials of Bempedoic Acid in Pediatric Heterozygous and Homozygous Familial Hypercholesterolemia

GlobeNewswire 5 days ago

Esperion Reports Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire March 4, 2025

Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia

GlobeNewswire March 3, 2025

Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4

GlobeNewswire February 18, 2025

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire February 13, 2025

Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET.

GlobeNewswire January 9, 2025

Esperion to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 2, 2025

Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions

GlobeNewswire December 18, 2024
View More News ››

Opinion & Analysis (NDAQ:ESPR)

Topline Results from Lipid-Lowering Trial 'Just What the Doctor Ordered'

Streetwise Reports September 5, 2019

Biopharma Buys 'Insurance Policy Ahead of First Commercial Launch'

Streetwise Reports July 3, 2019
View More Opinion ››

Bullboard Posts (NDAQ:ESPR)

Esperion Announces $210 Million Convertible Debt Financing

BREAKING NEWS: $ESPR Esperion Announces $210 Million Convertible Debt FinancingANN ARBOR, Mich., Dec. 13, 2024 (GLOBE NEWSWIRE...
whytestocks - December 13, 2024

This stock is a good buy

Buy Order was filled at $2.83 cents per share today and this one should do well for all of us shareholders.
coolfooldumbguy - December 2, 2024

Esperion Therapeutics, Inc.: Delivering Impressive Growth an

http://beyondspx.com/2024/07/31/esperion-therapeutics-inc-delivering-impressive-growth-and-expanded-indications/
MikeTester - August 2, 2024

ESPERION: REVOLUTIONIZING THE PHARMA INDUSTRY

$ESPR   Excited to share an article about Esperion Therapeutics Inc. (NASDAQ: ESPR), a pharmaceutical company...
AviseAnalytics - July 15, 2024

Esperion Reports First Quarter 2024 Financial Results

BREAKING NEWS: $ESPR Esperion Reports First Quarter 2024 Financial Results@ Q1 Total Revenue Grew 467% Y/Y to $137.7 Million, Reflecting...
whytestocks - May 7, 2024

Esperion to Report First Quarter 2024 Financial Results on M

News; $ESPR Esperion to Report First Quarter 2024 Financial Results on May 7ANN ARBOR, Mich., April 23, 2024 (GLOBE NEWSWIRE...
whytestocks - April 23, 2024
View more Bullboard ››

Fiddlehead Resources Corp.

Fiddlehead Resources Corp.

Fiddlehead Resources Corp. is a TSXV listed Cardium-focused oil and gas producer with 1,750 boepd of low decline, high ...
View More »